In contrast, VLDLR deletion in the mother alters milk metabolism, which inhibits osteoclast differentiation and causes osteopetrosis in the offspring. The maternal effects are dominant. VLDLR-null lactating mammary gland exhibits higher mTORC1 signaling and cholesterol biosynthesis. Pharmacological probing reveals that rapamycin, but not statin, treatment of the VLDLR-null mother can prevent both the low bone resorption and our previously described inflammatory fur loss in their offspring. Genetic rescue reveals that maternal mTORC1 attenuation in adipocytes, but not in myeloid cells, prevents offspring osteopetrosis and fur loss. Our studies uncover functions of VLDLR and mTORC1 in lactation and osteoclastogenesis, illuminating key mechanisms and therapeutic insights for bone and metabolic diseases.
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In Brief
Huynh et al. report that osteoclastogenesis and bone resorption are enhanced by offspring VLDLR deletion due to augmented RANKL signaling but impaired by maternal VLDLR deletion due to excessive mTOR signaling in the lactating mammary gland, providing key insights for VLDLR functions, milk metabolism, and maternal regulation of offspring traits.
INTRODUCTION
Mother's breast milk is the ideal nourishment for infants before they are able to eat and digest solid foods. Evolution has perfected the composition of breast milk so that it confers multiple key functions essential for newborn development. It provides not only macro-and micronutrients for the growth and development of the newborns (Gribble, 2006; Walker, 2010) but also hormones, digestive enzymes, and immune-defensive factors, including antibodies and cytokines (Bertotto et al., 1990; Gartner et al., 2005) . Given breast milk is a pristine source of energy, nutrients, and immunity for infants, defects in milk composition will have detrimental consequences for the offspring. Therefore, an understanding of the mechanisms by which mother's milk nourishes and protects the newborns is fundamentally important in order to design better infant formula and diagnostic/therapeutic strategies for infantile and childhood diseases.
Very-low density lipoprotein receptor (VLDLR) is a member of the low density lipoprotein (LDL) receptor family (Herz et al., 2009) . Discovered in 1992, VLDLR is highly expressed in tissues with active triglyceride metabolism, such as adipose tissue, heart, and skeletal muscle, but absent from the liver (Oka et al., 1994; Takahashi et al., 1992) . It plays an important role in the delivery of free fatty acids from VLDL triglycerides to various tissues as energy source (Tiebel et al., 1999; Webb et al., 1994) . VLDLR and apolipoprotein receptor 2 (APOER2) also form a heterodimeric receptor for reelin to regulate brain development (Trommsdorff et al., 1999) . However, little is known about VLDLR functions in other biological processes.
Our previous work shows that maternal VLDLR deletion causes milk defects, leading to systemic inflammation in nursing neonates manifested as transient fur loss (Du et al., 2012) . Here, we investigate whether these maternal and milk defects have any long-term effects on offspring traits, such as bone. Furthermore, studies from our group and others reveal that lipid metabolism intimately connect with skeletal homeostasis through several factors, including PPARg and ERRa (Wan, 2010; Wei et al., 2010 Wei et al., , 2016 . In this study, we uncover VLDLR as an important dual regulator of skeletal remodeling that plays opposite roles in the offspring and lactating mother.
RESULTS

Offspring VLDLR Suppresses Osteoclastogenesis and Bone Resorption
We crossed VLDLR +/À mice with VDLDR +/À mice to obtain VLDLR À/À mice and wild-type (WT) littermate control mice (Figure 1A) . Bodyweight or bone marrow cellularity was unaltered in VLDLR À/À mice (Figures S1A-S1D). To investigate the intrinsic role of VLDLR in osteoclastogenesis, we employed an ex vivo bone marrow osteoclast differentiation system . In this system, bone marrow osteoclast progenitors and precursors were first expanded using macrophage colony stimulating factor (M-CSF) and then differentiated into osteoclasts using RANKL, with or without further stimulation with rosiglitazone, a synthetic agonist for the pro-osteoclastogenic nuclear receptor PPARg . Compared with WT control cultures, both RANKL-induced and rosiglitazonestimulated osteoclast differentiation was enhanced in VLDLR À/À cultures, shown by tartrate-resistant acid phosphatase (TRAP) staining ( Figure 1B ), expression of osteoclast markers (Figure 1C) , and resorptive activity ( Figure 1D ). Osteoclast precursor proliferation or apoptosis was unaffected (Figures S1E and S1F) . In addition, the levels of RANKL, M-CSF, or osteoprotegerin (OPG) in bone were unchanged ( Figure S1G ). These observations indicate that VLDLR deletion mainly augments RANKL signaling during osteoclast differentiation. VLDLR was expressed not only in osteoclast ( Figure S1H ) but also in osteoblast ( Figure S1I ). However, ex vivo bone marrow osteoblast differentiation was normal ( Figures S1J and S1K) .
We next compared the in vivo bone phenotype. Consistent with our ex vivo osteoclastogenesis assay, ELISA analyses showed that serum bone resorption marker CTX-1 (carboxy-terminal telopeptides of type I collagen) was higher in VLDLR À/À mice ( Figure 1E ). Interestingly, despite the unaltered intrinsic ability of VLDLR À/À bone marrow mesenchymal stem cells to differentiate into osteoblasts (Figures S1J and S1K), serum bone formation marker P1NP (amino-terminal propeptide of type I procollagen) ( Figure 1F ), as well as bone formation rate and mineral apposition rate measured by double calcein labeling dynamic histomorphometry (Figures S1L-S1N), were decreased in VLDLR À/À mice, possibly due to changes in non-cell-autonomous signals.
Micro-computed tomography (mCT) of the trabecular bones in proximal tibiae showed that VLDLR À/À mice exhibited a low-bone-mass/osteoporosis phenotype ( Figures 1G-1M) , with decreased bone volume/tissue volume ratio (BV/TV) ( Figure 1H ), bone surface (BS) ( Figure 1I ), trabecular number (Tb.N) (Figure 1J) , and connectivity density (Conn.D) ( Figure 1L ), as well as increased trabecular separation (Tb.Sp) ( Figure 1K ) and structure model index (SMI), which quantifies the relative amount of plates (SMI = 0, strong) and rods (SMI = 3, fragile) ( Figure 1M ). In accordance with the serum bone marker ELISA results, static bone histomorphometry showed that femurs of VLDLR À/À mice exhibited higher osteoclast number and surface ( Figures  1N and 1O ) but lower osteoblast number and surface (Figures 1P and 1Q) . To determine whether the increased bone resorption originated from hematopoietic cells or stromal cells, we performed bone marrow transplantation in which total bone marrow from WT or VLDLR À/À donors was transferred into lethally irradiated WT recipients. The results showed that VLDLR À/À bone marrow was sufficient to confer increased bone resorption and decreased bone mass ( Figures 1R-1T ), indicating an osteoclast-intrinsic role of VLDLR. Dissection of RANKL downstream signaling events showed that VLDLR À/À osteoclast differentiation cultures displayed a faster and stronger activation of ERK1/2, AKT, and c-Jun ( Figure 1U ). These results indicate that VLDLR in osteoclast suppresses osteoclastogenesis and bone resorption.
Maternal VLDLR Enhances Offspring
Osteoclastogenesis and Bone Resorption via Milk Surprisingly, we found that VLDLR À/À mice from VLDLR À/À 3 VLDLR À/À breeding, designated as knockout (KO) (KO 3 KO) ( Figure 2A ) instead showed decreased ex vivo bone marrow osteoclast differentiation (Figures 2B and 2C) and in vivo osteoclast number/surface ( Figure 2D ) compared with WT mice from WT x WT breeding, designated as WT (WT 3 WT). As we previously reported, pups nursed by VLDLR À/À mothers develop transient fur loss ( Figure 2A ) and growth retardation (Figures S2A and S2B) due to a systemic inflammatory response to defective milk (Du et al., 2012) . This suggests that the blunted osteoclastogenesis in the offspring may result from maternal defects and milk disorders. As often observed in osteopetrotic mice with low bone resorption , KO (KO 3 KO) mice also displayed splenomegaly, possibly due to compromised hematopoiesis in the marrow ( Figures S2C and S2D ). Indeed, KO (KO 3 KO) mice had a lower total bone marrow cell number (Figure S2E) without overtly affected hematopoietic lineage allocation ( Figure S2F ), suggesting a reduction of hematopoiesis in the marrow, but not any lineage shift. Osteoclast precursor proliferation or apoptosis was unaltered in KO (KO 3 KO) bone marrow cultures (Figures S2G and S2H) , indicating that the defects mainly reside in osteoclast differentiation. To determine whether the bone phenotype in KO (KO 3 KO) mice originate from maternal or offspring genotype and prenatally or postnatally, we performed cross-fostering experiments ( Figure 2E ). WT 3 WT and KO 3 KO breeding were set up at the same time, and mothers that gave birth around the same day were used as foster pairs. On postnatal day 0-1, 50% of WT (WT 3 WT) pups were transferred to and nursed by KO lactating females; at the same time, 50% of KO (KO 3 KO) pups were transferred to and nursed by WT counterparts. Compared with WT pups nursed by WT moms, both ex vivo Figure 2H ) were enhanced for KO pups nursed by WT moms but blunted in WT pups nursed by KO moms, indicating that the reduced osteoclastogenesis was due to a postnatal maternal defects in the KO moms, likely through milk disorders. Moreover, KO pups nursed by KO moms showed a phenotype similar to WT pups nursed by KO moms rather than KO pups nursed by WT moms, indicating that the maternal effects were dominant ( Figures 2E-2H ). In contrast, bone formation marker was unaffected by the maternal defects ( Figure 2I ). mCT showed that compared with WT pups nursed by WT moms, KO pups nursed by WT moms exhibited low bone mass causing osteopenia/osteoporosis, whereas both WT and KO pups nursed by KO moms exhibited high bone mass causing osteopetrosis ( Figures 2J and 2K ). Our data indicate that maternal VLDLR plays an opposite and dominant role over offspring VLDLR to enhance offspring osteoclastogenesis and bone resorption by maintaining a normal milk composition.
Maternal VLDLR Deletion Accumulates Cholesterol Precursors in Milk
VLDLR is highly expressed in adipocyte-containing tissues (Yagyu et al., 2002) , including the mammary glands (Macias and Hinck, 2012) . To pinpoint the lactation defects, we collected lactating mammary glands on lactation day 2 (early lactation), day 10 (peak lactation), and day 18 (late lactation/early involution). Initial examination of the expression of genes associated with milk production revealed no significant changes between KO and WT glands ( Figure S3A ). Because VLDLR is closely related to LDLR, an important modulator of cholesterol metabolism, we tested whether cholesterol biosynthetic pathway was affected. We found that both mRNA and protein of the rate-limiting enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) was higher in the KO glands during peak lactation on day 10 ( Figures 3A and 3B ). The elevated HMGCR expression was absent during early lactation on day 2 but continued to late lactation on day 18 ( Figures S3B-S3D ). In addition, the expression of several other intermediate enzymes in the cholesterol biosynthetic pathway was also increased on day 10 ( Figure 3A) . Interestingly, the expression of lathosterol 5-desaturase (SC5D) was decreased in the KO glands throughout lactation ( Figures 3A, S3B , and S3C). SC5D catalyzes the second to the last step of cholesterol biosynthesis to convert lathosterol to 7-dehydrocholesterol in the KandutschRussel pathway or convert cholesta-7,24-dien-3b-ol to 7-dehydrodesmosterol in the Bloch pathway (Porter and Herman, 2011) .
Because HMGCR is critically regulated by SREBP family of transcription factors (Horton et al., 2002) , we next examined the expression of SREBP1-a, SREBP1-c, and SREPP1-2 in lactating mammary glands. SREBP-2 was upregulated in the KO glands, whereas SREBP1-a and SREBP1-c were unaltered (Figures 3C, S3E, and S3F) . This suggests that VLDLR inhibits SREBP-2, but not SREBP-1, to suppress HMGCR and cholesterol biosynthesis.
The combination of higher HMGCR and lower SC5D in the KO glands suggests an accumulation of cholesterol precursors, but not necessarily cholesterol itself. Intriguingly, cholesterol precursor accumulation has been reported to cause hair growth defects , suggesting that this may contribute to the milk disorders in question. To test this hypothesis, we collected milk from WT and KO moms on lactation day 11 and performed gas chromatography-mass spectrometry (GC-MS) to quantify cholesterol and precursors ( Figure 3D ). Lanosterol, 24,25-dihydrolanosterol, zymosterol, lathosterol, and 7-dehydrocholesterol levels were increased in the KO milk compared with WT control milk, whereas desmosterol and cholesterol levels were not different ( Figure 3D ). Consistent with the comparable milk cholesterol levels between WT and KO, serum cholesterol levels were also unaltered in KO lactating moms ( Figure S3G ).
To evaluate if cholesterol precursor accumulation in the KO milk mediates the phenotype in the pups, we treated lactating KO moms with 100 mg/kg simvastatin every other day for 21 days since parturition via intraperitoneal injection. Maternal treatment with simvastatin partially rescued pup fur loss (Figure 3E) , but the rescuing effect was short-term, as the next litter from the same mom without further simvastatin treatment reverted back to full fur loss ( Figure 3E ). However, maternal simvastatin treatment could not rescue the low bone resorption in the pups (Figures 3F and 3G) . These results suggest that cholesterol precursor accumulation in milk may contribute to fur loss but does not play a major role in the osteopetrosis of offspring.
Maternal mTORC1 Inhibition by Rapamycin Rescues Offspring Osteopetrosis and Alopecia
Gene expression analysis also revealed a marked reduction of lipin 1 (LPIN1) in the KO glands on days 10 and 18 ( Figure S4A ). Lipin 1, a phosphatidic acid phosphatase, is regulated by mTOR complex 1 (mTORC1) to control the SREBP pathway (Peterson (legend continued on next page) et al., 2011). Moreover, an induction of tuberous sclerosis 1 and 2 (TSC1/2) in KO glands on day 10 ( Figure 3C ) suggests a feedback inhibition of mTORC1. Akt is an upstream activator of mTORC1, while S6K1 and S6 are downstream targets of mTORC1 (Laplante and Sabatini, 2012) . Indeed, higher levels of phosphorylated Akt, S6K1, and S6 were observed in the KO glands on days 10 and 18 ( Figures 4A and S4B ), indicating higher mTORC1 activity. This activated mTORC1 signaling was not due to changes in ERK1/2 mitogen-activated protein (MAP) kinases ( Figures S4C and S4D) .
To test if pharmacologic inhibition of mTORC1 could rescue pup phenotype, we treated lactating KO moms with 25 mg/kg rapamycin every other day for 21 days following parturition via intraperitoneal injection. Maternal rapamycin treatment effectively prevented fur loss ( Figure 4B ) and, remarkably, low bone resorption and high bone mass in their pups ( Figures 4C-4I ). The rescue was short-term, without lasting until the next litter ( Figures 4B-4I) .
Rapamycin reversed the elevated expression of HMGCR, SREBP2, and TSC1/2 in the KO glands ( Figures 4J, 4K , S4E, and S4F) as the result of mTORC1 signaling suppression ( Figures  S4I-S4K ). Moreover, rapamycin also reversed the elevated expression of pro-inflammatory adipokines tumor necrosis factor alpha (TNF-a), interleukin 6 (IL-6), IL-1b, and IL-18 in KO glands ( Figures 4L and S4G ). In addition, we examined the expression of several enzymes of the arachidonic acid pathway, including prostaglandin synthases, lipoxygenases, and cyclooxygenases, as a recent study showed that prostaglandins promote alopecia (Garza et al., 2012) . PTGIS, PTGDS, and PTGES levels were elevated in KO glands on day 10 but reduced back to control levels on day 18. COX1 and ALOX15 levels were also higher in KO glands on days 10 and 18. Rapamycin treatment also effectively abolished the upregulation of these genes in KO glands ( Figures 4M and S4H) . Therefore, mTORC1 inhibition by rapamycin exerted multiple actions to more effectively prevent milk disorders and offspring defects compared with HMGCR inhibition by simvastatin alone.
Genetic mTORC1 Attenuation in Adipocyte Rescues
Offspring Osteopetrosis and Alopecia To confirm our pharmacological findings that excessive mTORC1 mediates the milk disorder, and to dissect the key cell type in which mTORC1 acts, we next performed genetic rescue experiments. Since adipocytes and macrophages are two major cell types in the lactating mammary gland, we disrupted mTORC1 functions in these two cell types by crossing Raptor flox mice with lysozyme (Lyz)-Cre or adiponectin (Adipo)-Cre to generate macrophage-and adipocyte-specific Raptor KO mice, respectively ( Figure S5) . These mice were then crossed with VLDLR À/À mice to generate compound mutants in order to assess rescuing effects. Both fur loss and osteopetrosis in the offspring were effectively rescued by adipocyte Raptor deletion, but not by macrophage Raptor deletion, in VLDLR-KO moms ( Figures 5A-5I ). Although acute maternal rapamycin treatment did not significantly improve the body weight in the pups ( Figure S4L ), maternal genetic Raptor deletion in adipocytes, but not in macrophages, did significantly prevent growth retardation ( Figure 5J ). These results not only confirmed mTORC1 as a key VLDLR downstream signaling to control milk metabolism and offspring traits but also pinpoint adipocytes as the crucial site of regulation.
DISCUSSION
This study reveals a yin-yang dual role of VLDLR in the regulation of osteoclastogenesis and bone resorption ( Figure 5K ). On one hand, VLDLR in the offspring suppresses osteoclast differentiation by inhibiting RANKL signaling such as ERK/Akt/c-Jun phosphorylation. The cell-autonomous regulation of osteoclast differentiation by offspring VLDLR is demonstrated by the following findings: (1) VLDLR À/À osteoclast precursors exhibit a significantly higher ability for osteoclast differentiation in the absence of stromal cells (Figures 1B and 1D) . (2) VLDLR À/À osteoclast differentiation cultures exhibit hypersensitivity to RANKL signaling, including augmented activation of NFATc1, c-Fos, ERK, AKT, and c-Jun in the absence of stromal cells ( Figures 1C and 1U ).
(3) RANKL, M-CSF, and OPG levels in bone were unaltered, indicating that the enhanced osteoclastogenesis in vivo is due to increased cytokine sensitivity rather than cytokine abundance ( Figure S1G ). (4) Bone marrow chimera with VLDLR À/À bone marrow cells showed that the elevated bone resorption mainly originates from hematopoietic cells rather than stromal cells (Figures 1R-1T ). On the other hand, VLDLR in the nursing mother dominantly promotes offspring osteoclastogenesis by attenuating mTORC1 signaling in the lactating mammary gland to prevent milk metabolic and inflammatory disorders ( Figure 5K ). Consequently, maternal VLDLR deletion causes decreased osteoclast differentiation and bone resorption in offspring, leading to higher bone mass (Figure 2 ), owing to excessive maternal mTORC1 activities (Figure 4) . The functional significance of mTORC1 is illustrated by the ability of maternal rapamycin treatment to effectively abrogate the bone defects in the offspring (Figure 4) . Moreover, the adipocyte is the major cell type of excessive maternal mTORC1 activity, because Raptor deletion therein rescues the offspring bone phenotype ( Figure 5 ). Together, these findings unveil VLDLR as an important yet previously unrecognized player in skeletal homeostasis and lactation metabolism that exerts cross generation regulation. The transient osteopetrosis and alopecia in the offspring nursed by VLDLR-KO mothers are mainly due to milk defects. Fostering experiments show that these offspring traits are strictly conferred by the VLDLR-KO lactating mother but independent of the genotype of the birth mother, father, or pups. Moreover, the impaired osteoclastogenesis in offspring nursed by VLDLR-KO mothers persists for 2 months after weaning but becomes rescued by 3 months after weaning ( Figures S2I-S2K ). This is likely due to the dilution of the milk effects and the turnover of bone cells, as the literature shows that the lifespan of osteoclast and osteoblast is $2 weeks and 3 months, respectively (Manolagas, 2000) . Initially, we hypothesized that the transmission of maternal defects to the offspring may be also contributed by microbiota. However, when we cross-transferred cage bedding and feces between WT and KO moms, we did not observe the switch of pup phenotype, indicating that microbiota do not play a major role in this context. Together, our findings support that milk is responsible for the maternal VLDLR control of offspring traits. Initially, the observation of a dramatic increase in HMGCR expression in the lactating mammary gland prompted us to investigate the significance of milk cholesterol in the offspring bone and fur loss phenotype. However, our data indicate that the cholesterol pathway may be a factor contributing to, but not the major mediator of, the phenotype in question. Based on our maternal pharmacological experiments showing a stronger rescue by rapamycin than by simvastatin, we decided to instead focus on mTORC1 signaling. Our findings suggest that multiple pathways in the mom may contribute to the milk defect and pup phenotype, but mTORC1 is the master regulator, because rapamycin treatment corrected several defects in the lactating mammary gland, including cholesterol pathway and inflammatory signaling (Figures 4J-4M ). Our study focuses on the moms and the lactating mammary gland; thus, we treated the lactating moms (rather than pups) with simvastatin or rapamycin. It is possible that the extent to which cholesterol defects contribute to these phenotypes was not fully revealed by simvastatin treatment due to dosage limitation, and future studies using genetic approaches will be required to further elucidate.
Our previous histological analysis of the skin of the pups nursed by VLDLR À/À moms revealed that the transient fur loss was due to an early ejection of the hair shaft upon inflammation rather than hair follicle formation defects (Du et al., 2012) . Although the pups lost their fur and developed follicular cyst in the skin, the hair bulbs/follicles appeared normal and similar to the pups nursed by WT moms; hypodermal adipocytes in the skin were also comparable as controls (Du et al., 2012) . In contrast, the skin histology from published mouse models that lose their fur due to cholesterol defects, such as epidermal-specific (Epi)-Insig1/2-DKO , LDLR/ApoAI double-KO (Zabalawi et al., 2007) , ACAT1 KO, ApoE KO, or ACAT1/ LDLR double-KO mice (Yagyu et al., 2000) , showed that hair bulbs/follicles, as well as subcutaneous adipocytes, were largely absent. In addition, VLDLR is known to mediate VLDL uptake and free fatty acid delivery; however, it does not play as an important role as LDLR in cholesterol metabolism (Nimpf and Schneider, 2000; Oka et al., 1994) , supporting the differential functions by VLDLR and LDLR. Collectively, these findings indicate that the fur loss in the pups nursed by VLDLR À/À moms may be contributed by milk cholesterol metabolic defects but may be distinct from or less severe than the fur loss in these published genetic mouse models with cholesterol defects. In Epi-Insig-DKO mice, topical treatment with simvastatin reduced sterol precursors in skin and corrected the hair and skin defects ). Since our current study focuses on VLDLR À/À lactating moms, future studies will be needed to determine in their pups whether topical simvastatin treatment can rescue fur loss and systemic simvastatin treatment can rescue low bone resorption.
We have investigated extensively the milk factors that may confer the pup phenotype by gavaging WT nursing pups with individual inflammatory cytokines or lipids such as cholesterol precursors. The results show that none of them alone is sufficient to replicate the pup phenotype, indicating that multiple inflammatory and metabolic milk factors from VLDLR-KO mom are simultaneously required to exert these consequences in the pups. Both inflammatory pathways and lipid metabolism are known downstream targets of mTORC1 signaling, revealing mTORC1 as a master regulator of lactation that confer these pleotropic changes.
It is well known that Akt activates mTORC1 by inhibiting mTORC1 suppressors TSC1/2 (Guertin and Sabatini, 2007; Zoncu et al., 2011) . It is also known that acute rapamycin inhibition of mTORC1/S6K often increases Akt due to compensatory effects by alleviating a negative feed-back loop (Chaturvedi et al., 2009; Harrington et al., 2004; Manning, 2004; Um et al., 2004; . Indeed, we found that short-term treatment of VLDLR À/À moms with rapamycin suppressed mTORC1 activity but increased Akt signaling ( Figure S4J ). Virgin mammary glands are essentially fat pads such as inguinal fat; during pregnancy and lactation, mammary glands/ fat pads undergo epithelial expansion, and the glands turn into largely mammary epithelial cells (Inman et al., 2015) . As an important stromal cell type, adipocyte regulates mammary epithelial cell functions by providing an energy source and acting as an endocrine organ (Hovey and Aimo, 2010; Inman et al., 2015) . Moreover, there is evidence suggesting that adipocyte and mammary epithelial cells undergo reversible trans-differentiation (Morroni et al., 2004) . Therefore, Raptor deletion in adipocytes likely modulates mammary epithelial functions during lactation via both direct and indirect effects, by controlling multiple metabolic and inflammatory pathways.
Our current study reveals adipocyte as a key cell type for mTORC1 regulation during lactation. Our previous studies showed that macrophages are also important for maternal PPARg and VLDLR modulation of milk composition and offspring phenotype. These findings reveal that cellular crosstalk in the lactating mammary gland between adipocytes and macrophages may modulate milk composition and lactation outcome by balancing metabolism and immunity. For example, as we discussed in our earlier study (Wan et al., 2007c) , PPARg deficiency in macrophage may produce more endogenous PPARg ligands, such as HODES/HETES, that can activate PPARg in the mammary adipocytes to increase lipogenesis. Similarly, VLDLR deficiency in macrophage may alter adipocyte mTORC1 signaling and lipid homeostasis, leading to altered milk metabolism. Future studies are needed to further characterize this crosstalk.
Provocatively, our findings highlight that metabolic/inflammatory/bone diseases in the offspring may originate from maternal defects and milk disorders, which can be prevented by maternal interventions such as rapamycin treatment. Mechanistically, our work reveals a key signaling pathway in the lactating mammary gland in which VLDLR inhibits mTORC1 activities in the adipocyte to suppress cholesterol biosynthesis by downregulating the expression of SREBP2 and HMGCR, as well as to suppress the expression of inflammatory adipokines and prostaglandin synthases. These combined actions tightly control milk metabolism and immunity to ensure milk quality and optimal development of the offspring. Pharmacologic inhibition of HMGCR with simvastatin did not rescue low bone resorption and only partially rescued fur loss in the pups nursed by VLDLR-KO moms, suggesting that the milk disorder was more than just altered cholesterol biosynthesis and accumulation of cholesterol precursors. In addition to regulating many cellular processes that control organismal growth and homeostasis, including protein synthesis, autophagy, metabolism, and lipogenesis, mTORC1 has become increasingly appreciated to also play important roles in immunity and inflammation. Indeed, the exacerbated mTORC1 signaling in the VLDLR-KO lactating mammary glands leads to increased levels of inflammatory adipokines and prostaglandin synthases. The pleiotropic effects of mTORC1 on both metabolism and inflammation establish mTORC1 as a master regulator of lactation and VLDLR function, and rapamycin as an effective treatment of milk disorders and associated offspring diseases. Moreover, our genetic dissection pinpoints the adipocyte as the main site of mTORC1 action in the lactating mammary gland, further highlighting the important roles of adipocytes at the crossroads of metabolism and immunity.
EXPERIMENTAL PROCEDURES
VLDLR
À/À mice , Raptor flox mice (Sengupta et al., 2010) , Lysozyme-Cre and Adiponectin-Cre transgenic mice were from Jackson Laboratory and maintained on C57BL/6 background. Mice were fed standard rodent chow ad libitum (Harlan Laboratories). 9-to 10-week-old females were used for breeding. Litter sizes were normalized to six pups. Milk was collected as described previously (Wan et al., 2007c) . Sterol precursors and cholesterol in milk were analyzed by GC-MS as described previously . To obtain VLDLR ;Adiponectin-Cre (or Lysozyme-Cre) were bred with WT male mice. For treatment, lactating female mice received intraperitoneally 25 mg/kg rapamycin, 100 mg/kg simvastatin, or vehicle control every other day for 21 days since parturition. All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern Medical Center. Bone marrow osteoclast/osteoblast differentiation, bone analyses, and gene expression were performed as described previously . All statistical analyses were performed with the Student's t test, and results are presented as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; and n.s., nonsignificant [p > 0.05)]. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Mice VLDLR -/-mice , Raptor flox mice (Sengupta et al., 2010) , Lysozyme-Cre and Adiponectin-Cre transgenic mice were from Jackson Laboratory and maintained on C57BL/6 background. Mice were fed standard rodent chow ad libitum (Harlan Laboratories). To generate VLDLR -/-and WT littermates, VLDLR +/-female were bred with VLDLR +/-male mice. For cross-fostering, 9-10-week-old female VLDLR -/-or WT control mice were bred to VLDLR -/-or WT male mice, respectively. Female mice that gave birth around the same day were used as foster pairs. Litter sizes were normalized to 6 pups. On postnatal day 0-1, 50% of VLDLR -/-progenies were transferred to WT parents, or vice versa. For milk collections and analyses, 9-10-week-old female VLDLR -/-or WT control mice were bred to WT male mice. Litter sizes were normalized to 5-6 pups. Milk was collected as described . On lactation day 8-12, lactating females were separated from their pups for 3-5 hr to allow the mammary glands to refill. Before milking, the lactating female was anaesthetized with an i.p. injection of avertin (0.4 ml of a 20-mg/ml stock), and then i.p. injected with 0.5 U of oxytocin (0.2 ml of a 2.5 U/ml stock) to induce milk ejection. Milk was immediately collected from mammary glands by gentle vacuum suction through a capillary tube. All ten mammary glands were milked two rounds for a total of 20 min per mouse, allowing the collection of most of the milk. Sterol precursors and cholesterol in milk were analyzed by gas chromatography-mass spectrometry (GC-MS) as previously described . To 
Bone Marrow Osteoclast and osteoblast Differentiation
Osteoclasts were differentiated from bone marrow cells as previously described . Briefly, bone marrow cells were differentiated with 40 ng/ml of mouse M-CSF (R&D Systems) in α-MEM containing 10% FBS for 3 days (day 1-3), then with 40 ng/ml of mouse MCSF and 100 ng/ml of mouse RANKL (R&D Systems) for 3-7
